{
    "clinical_study": {
        "@rank": "105949", 
        "arm_group": [
            {
                "arm_group_label": "AR11 (amphetamine sulfate)", 
                "arm_group_type": "Experimental", 
                "description": "AR11, administered orally, BID, 10-40 mg/day"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "administered orally, BID"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a dose-optimized, randomized, double-blind, placebo-controlled crossover study in\n      approximately 100 pediatric patients (aged 6 to 12 years) with ADHD. Eligible patients will\n      enroll in the study to take open-label AR11 twice daily and undergo dose optimization\n      activities for 8 weeks. Patients who achieve a stable dose during the dose optimization\n      period will continue participation and will be randomized to take double-blind medication\n      (AR11 or placebo) orally twice daily for 1 week. At the end of the first double-blind\n      treatment period, patients will be evaluated for ADHD symptoms in a laboratory classroom\n      setting utilizing SKAMP and PERMP assessments. At the end of the second double blind\n      treatment period, patients will be evaluated for ADHD symptoms in a second laboratory\n      classroom setting utilizing SKAMP and PERMP assessments."
        }, 
        "brief_title": "Crossover Study to Evaluate the Efficacy of AR11 in Pediatric Patients With ADHD in a Laboratory Classroom Setting", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Attention Deficit Hyperactivity Disorder (ADHD)", 
        "condition_browse": {
            "mesh_term": [
                "Attention Deficit Disorder with Hyperactivity", 
                "Hyperkinesis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Male or female between 6 and 12 years of age, inclusive, at the time of Screening.\n\n          2. Diagnosed as meeting Diagnostic and Statistical Manual of Mental Disorders, Fourth\n             Edition, Text Revision (DSM-IV-TR) criteria for ADHD.\n\n          3. A clinician-administered Clinical Global Impression of Severity (CGI-S) score of 3 or\n             greater.\n\n          4. An ADHD Rating Scale (ADHD-RS) score at Screening and Baseline greater than or equal\n             to the 90th percentile normative values for gender and age in at least one of the\n             following categories: hyperactive-impulsive subscale, inattentive subscale, or total\n             score.\n\n        Exclusion Criteria:\n\n          1. Secondary or co-morbid diagnoses other than ADHD, with the exception of simple\n             phobias, oppositional defiant disorder, elimination disorders, motor skills\n             disorders, communication disorders, learning disorders, adjustment disorders, and\n             sleep disorders if, in the opinion of the investigator, the associated symptoms do\n             not confound assessment of safety or efficacy.\n\n          2. Clinically significant cognitive impairment as assessed in the clinical judgment of\n             the Investigator.\n\n          3. History of any of the following medical disorders:  seizure disorder (excluding a\n             history of febrile seizures), structural cardiac disorders, serious cardiac\n             conditions, hypertension, untreated thyroid disease, glaucoma, Tourette's disorder,\n             or chronic tics.\n\n          4. Clinically significant abnormal ECG finding or abnormal cardiac finding on physical\n             exam (including presence of a pathologic murmur) at Screening.\n\n          5. Use of any psychotropic medication (sedative hypnotics prescribed as a sleep aid at a\n             stable dose for at least 30 days prior to Baseline, at bedtime only, are allowed\n             during the study).\n\n          6. A history of hypersensitivity or intolerance to any formulation of amphetamine or\n             lisdexamfetamine."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "12 Years", 
            "minimum_age": "6 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01986062", 
            "org_study_id": "AR11.001"
        }, 
        "intervention": {
            "arm_group_label": "AR11 (amphetamine sulfate)", 
            "intervention_name": "AR11", 
            "intervention_type": "Drug", 
            "other_name": "amphetamine sulfate"
        }, 
        "intervention_browse": {
            "mesh_term": "Amphetamine"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "ADHD", 
            "AR11", 
            "classroom design", 
            "amphetamine sulfate"
        ], 
        "lastchanged_date": "March 18, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Bradenton", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "34201"
                    }, 
                    "name": "Florida Clinical Research Center, LLC."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Maitland", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32751"
                    }, 
                    "name": "Florida Clinical Research Center, LLC"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "South Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33143"
                    }, 
                    "name": "Miami Research Associates"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Las Vegas", 
                        "country": "United States", 
                        "state": "Nevada", 
                        "zip": "89128"
                    }, 
                    "name": "Center for Psychiatry and Behavioral Medicine, Inc."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Durham", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27705"
                    }, 
                    "name": "Duke University Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77007"
                    }, 
                    "name": "Bayou City Research Ltd."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "79423"
                    }, 
                    "name": "Westex Clinical Investigations"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Multicenter, Dose-Optimized, Double-Blind, Randomized, Placebo-Controlled, Crossover Study to Evaluate the Efficacy of AR11 (Amphetamine Sulfate) in Pediatric Patients (Ages 6-12) With Attention Deficit Hyperactivity Disorder (ADHD) in a Laboratory Classroom", 
        "overall_official": {
            "affiliation": "Arbor Pharmaceuticals, LLC.", 
            "last_name": "Laurence Downey, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Swanson, Kotkin, Agler, M-Flynn, and Pelham Scale [SKAMP]-combined scores measured during Laboratory Classroom Days", 
            "measure": "SKAMP-Combined scores", 
            "safety_issue": "No", 
            "time_frame": "Two hours post-dose"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01986062"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "SKAMP-Combined scores", 
                "safety_issue": "No", 
                "time_frame": "0.75, 4, 6, 8, and 10 hours post-dose"
            }, 
            {
                "measure": "SKAMP-Attention and -Deportment scores", 
                "safety_issue": "No", 
                "time_frame": "0.75, 2, 4, 6, 8, and 10 hours post dose"
            }, 
            {
                "description": "Permanent Product Measure of Performance (PERMP) assessments measured during Laboratory Classroom Days", 
                "measure": "PERM-P scores", 
                "safety_issue": "No", 
                "time_frame": "0.75, 2, 4, 6, 8, and 10 hours post-dose"
            }
        ], 
        "source": "Arbor Pharmaceuticals, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Arbor Pharmaceuticals, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}